drugset / Trial / NCT05933824
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LP-98 Injection in Healthy Subjects
Phase 1
Completed
36 enrolled
Shanxi Kangbao Biological Product Co., Ltd.
Institute of Pathogen Biology, Beijing, China · collab
RandomizedSequentialDouble-blindTreatment
Summary
A randomized, placebo-controlled, single-administration, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of LP-98 injection in healthy subjects in a first-in-human clinical study
Timeline
- Start
- 2023-07-13
- Primary completion
- 2024-04-12
- Completion
- 2024-04-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LP-98 | Unknown | 5 mg | Subcutaneous |
| Subject | LP-98 | Unknown | 10 mg | Subcutaneous |
| Subject | LP-98 | Unknown | 20 mg | Subcutaneous |
| Subject | LP-98 | Unknown | 40 mg | Subcutaneous |
| Subject | LP-98 | Unknown | 80 mg | Subcutaneous |
| Subject | LP-98 | Unknown | 160 mg | Subcutaneous |